Gallagher Carol Giltner — SEC insider filings
SEC reporting owner CIK 1329959. 20 insider filings on record with FilingPulse; latest filed 2026-10-08.
Transaction summary — filings shown
Covers all 20 filings on record, filed 2021-06-04 to 2026-10-08. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 1 filing — 270,000 shares, $68,214 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 36.
- Largest priced transaction: purchase of 179,020 shares @ $0.22 ($40,029) in Atara Biotherapeutics, Inc., filed 2023-11-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | Director | 6 | 2 legs · 270,000 sh · $68,214 | — | 8 |
| PMV Pharmaceuticals, Inc. (PMVP) | Director | 5 | — | — | 15 |
| Mirati Therapeutics, Inc. (MRTX) | Director | 3 | — | — | 6 |
| Turning Point Therapeutics, Inc. (TPTX) | Director | 2 | — | — | 4 |
| Certara, Inc. (CERT) | Director | 1 | — | — | 1 |
| Frazier Lifesciences Acquisition Corp (FLAC) | Director | 1 | — | — | 1 |
| TRex Bio, Inc. (TRXB) | Director | 2 | — | — | 1 |
Insider filings — Gallagher Carol Giltner
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-08 | 3 | TRex Bio, Inc. (TRXB) | Holdings only — no transactions reported | EDGAR |
| 2026-10-08 | 4 | TRex Bio, Inc. (TRXB) | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | PMV Pharmaceuticals, Inc. (PMVP) | Grant/award (A): 42,000 (derivative) @ $0 · Gift (G): 42,000 (derivative) @ $0 · Gift (G): 42,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Grant/award (A): 7,828 @ $0 | EDGAR |
| 2025-06-09 | 4 | PMV Pharmaceuticals, Inc. (PMVP) | Grant/award (A): 33,500 (derivative) @ $0 · Gift (G): 33,500 (derivative) @ $0 · Gift (G): 33,500 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | PMV Pharmaceuticals, Inc. (PMVP) | Grant/award (A): 67,500 (derivative) @ $0 · Gift (G): 67,500 (derivative) @ $0 · Gift (G): 67,500 (derivative) @ $0 | EDGAR |
| 2024-04-02 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Grant/award (A): 150,000 @ $0 | EDGAR |
| 2024-01-23 | 4 | Mirati Therapeutics, Inc. (MRTX) | Disposition to issuer (D): 7,555 · Disposition to issuer (D): 6,808 · Disposition to issuer (D): 12,784 (derivative) | EDGAR |
| 2024-01-03 | 4 | Mirati Therapeutics, Inc. (MRTX) | Grant/award (A): 6,808 @ $58.75 | EDGAR |
| 2023-11-15 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Purchase (P): 179,020 @ $0.22 · Purchase (P): 90,980 @ $0.31 | EDGAR |
| 2023-06-23 | 4 | Mirati Therapeutics, Inc. (MRTX) | Grant/award (A): 7,555 @ $0 · Grant/award (A): 12,784 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | PMV Pharmaceuticals, Inc. (PMVP) | Grant/award (A): 21,500 (derivative) @ $0 · Gift (G): 21,500 (derivative) @ $0 · Gift (G): 21,500 (derivative) @ $0 | EDGAR |
| 2023-06-02 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Grant/award (A): 57,000 @ $0 · Grant/award (A): 79,500 (derivative) @ $0 | EDGAR |
| 2022-11-23 | 4 | Frazier Lifesciences Acquisition Corp (FLAC) | Option exercise (M): 30,000 (derivative) | EDGAR |
| 2022-11-08 | 4 | PMV Pharmaceuticals, Inc. (PMVP) | Grant/award (A): 39,000 (derivative) @ $0 · Gift (G): 39,000 (derivative) @ $0 · Gift (G): 39,000 (derivative) @ $0 | EDGAR |
| 2022-08-17 | 4 | Turning Point Therapeutics, Inc. (TPTX) | Disposition to issuer (D): 8,500 (derivative) · Disposition to issuer (D): 8,500 (derivative) · Disposition to issuer (D): 30,000 (derivative) | EDGAR |
| 2022-06-27 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Grant/award (A): 20,500 @ $0 · Grant/award (A): 31,500 (derivative) @ $0 | EDGAR |
| 2021-06-16 | 4 | Certara, Inc. (CERT) | Grant/award (A): 7,059 @ $0 | EDGAR |
| 2021-06-09 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Grant/award (A): 11,000 @ $0 · Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | Turning Point Therapeutics, Inc. (TPTX) | Grant/award (A): 8,500 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-06-03 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1329959 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs